257,143 Shares in Mesoblast Limited $MESO Purchased by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. bought a new position in shares of Mesoblast Limited (NASDAQ:MESO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 257,143 shares of the company’s stock, valued at approximately $3,209,000. Goldman Sachs Group Inc. owned about 0.20% of Mesoblast at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in MESO. BNP Paribas Financial Markets lifted its holdings in Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after acquiring an additional 2,597 shares during the last quarter. Bank of America Corp DE raised its position in Mesoblast by 1,503.3% in the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company’s stock valued at $5,756,000 after purchasing an additional 272,595 shares during the period. GAMMA Investing LLC increased its position in shares of Mesoblast by 1,174.2% during the first quarter. GAMMA Investing LLC now owns 85,513 shares of the company’s stock worth $1,067,000 after acquiring an additional 78,802 shares during the period. Summit X LLC increased its position in shares of Mesoblast by 36.0% during the first quarter. Summit X LLC now owns 198,163 shares of the company’s stock worth $2,473,000 after acquiring an additional 52,508 shares during the period. Finally, Choreo LLC purchased a new stake in shares of Mesoblast during the first quarter worth $128,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MESO. Canaccord Genuity Group raised Mesoblast to a “strong-buy” rating in a research report on Tuesday, August 5th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $18.00.

Mesoblast Stock Up 4.5%

Shares of MESO opened at $15.75 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.99 and a quick ratio of 1.77. The firm has a 50 day simple moving average of $14.86 and a 200-day simple moving average of $12.76. Mesoblast Limited has a 1-year low of $6.14 and a 1-year high of $22.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.